Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

Researchers review the safety, efficacy, and considerations for COVID-19 vaccination in multiple sclerosis patients, especially those on disease-modifying therapies, affirming the vaccine's overall benefit in reducing severe COVID-19 risks without significantly increasing MS relapse rates.

On this episode of Managed Care Cast, hear from a multiple sclerosis (MS) specialist about how millennial patients are different (or not) in how they approach their disease.

As with other disease states, biomarkers that can provide value across diagnosis, prognosis, and treatment response, have been heavily sought out to help guide optimal treatment decisions throughout the course of disease.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

New data suggest the frequency of damage and repair processes correlates with disease severity and disability in multiple sclerosis (MS).

The therapy reduced inflammation and appeared to slow disease progression in models, suggesting it could have similar impacts in humans.